The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.
Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.
Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.
